Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Barbara Dapas"'
Autor:
Marianna Maddaloni, Rossella Farra, Barbara Dapas, Fulvia Felluga, Fabio Benedetti, Federico Berti, Sara Drioli, Mattia Vidali, Maja Cemazar, Urska Kamensek, Claudio Brancolini, Erminio Murano, Francesca Maremonti, Mario Grassi, Alice Biasin, Flavio Rizzolio, Enrico Cavarzerani, Bruna Scaggiante, Roberta Bulla, Andrea Balduit, Giuseppe Ricci, Gabriella Zito, Federico Romano, Serena Bonin, Eros Azzalini, Gabriele Baj, Domenico Tierno, Gabriele Grassi
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 664 (2024)
Background: The identification of novel therapeutic strategies for ovarian cancer (OC), the most lethal gynecological neoplasm, is of utmost urgency. Here, we have tested the effectiveness of the compound 2c (4-hydroxy-2,6-bis(4-nitrobenzylidene)cycl
Externí odkaz:
https://doaj.org/article/9cda9d91d298443aa1fd39a5f208d7da
Publikováno v:
Biomedicines, Vol 12, Iss 4, p 875 (2024)
Breast cancer (BC) is currently the most common neoplasm, the second leading cause of cancer death in women worldwide, and is a major health problem. The discovery of new biomarkers is crucial to improve our knowledge of breast cancer and strengthen
Externí odkaz:
https://doaj.org/article/7734563fd66b487a860c946b0cd48883
Autor:
Tanja Jesenko, Simona Kranjc Brezar, Maja Cemazar, Alice Biasin, Domenico Tierno, Bruna Scaggiante, Mario Grassi, Chiara Grassi, Barbara Dapas, Nhung Hai Truong, Michela Abrami, Fabrizio Zanconati, Deborah Bonazza, Flavio Rizzolio, Salvatore Parisi, Giorgia Pastorin, Gabriele Grassi
Publikováno v:
Pharmaceutics, Vol 15, Iss 4, p 1249 (2023)
Hepatocellular carcinoma (HCC) remains a global health challenge, representing the third leading cause of cancer deaths worldwide. Although therapeutic advances have been made in the few last years, the prognosis remains poor. Thus, there is a dire n
Externí odkaz:
https://doaj.org/article/7c7dcf89c2694849bf0728a6e1b2b462
Autor:
Nadia Halib, Nicola Pavan, Carlo Trombetta, Barbara Dapas, Rossella Farra, Bruna Scaggiante, Mario Grassi, Gabriele Grassi
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 718 (2022)
The treatment of urological cancers has been significantly improved in recent years. However, for the advanced stages of these cancers and/or for those developing resistance, novel therapeutic options need to be developed. Among the innovative strate
Externí odkaz:
https://doaj.org/article/c140d8fcb82e48399377d8e34ac51615
Autor:
Federica Tonon, Rossella Farra, Cristina Zennaro, Gabriele Pozzato, Nhung Truong, Salvatore Parisi, Flavio Rizzolio, Mario Grassi, Bruna Scaggiante, Fabrizio Zanconati, Deborah Bonazza, Gabriele Grassi, Barbara Dapas
Publikováno v:
Pharmaceuticals, Vol 14, Iss 8, p 803 (2021)
Hepatocellular carcinoma (HCC) is the sixth most common type of tumor and the second leading cause of tumor-related death worldwide. Liver cirrhosis is the most important predisposing factor for HCC. Available therapeutic approaches are not very effe
Externí odkaz:
https://doaj.org/article/6551edbe065c4a19a15a6801f64e5263
Autor:
Gianni Biolo, Filippo G. Di Girolamo, Adam McDonnell, Nicola Fiotti, Filippo Mearelli, Roberta Situlin, Arianna Gonelli, Barbara Dapas, Mauro Giordano, Mitja Lainscak, Gabriele Grassi, Giorgio Zauli, Paola Secchiero, Igor Mekjavic
Publikováno v:
Frontiers in Physiology, Vol 9 (2018)
In chronic diseases, hypoxia and physical inactivity are associated with atherosclerosis progression. In contrast, a lower mortality from coronary artery disease and stroke is observed in healthy humans residing at high altitude in hypoxic environmen
Externí odkaz:
https://doaj.org/article/b00fd7483e24452a86d3ed0c9f3a4d77
Autor:
Rossella Farra, Matea Maruna, Francesca Perrone, Mario Grassi, Fabio Benedetti, Marianna Maddaloni, Maguie El Boustani, Salvo Parisi, Flavio Rizzolio, Giancarlo Forte, Fabrizio Zanconati, Maja Cemazar, Urska Kamensek, Barbara Dapas, Gabriele Grassi
Publikováno v:
Pharmaceutics, Vol 11, Iss 10, p 547 (2019)
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as
Externí odkaz:
https://doaj.org/article/3b375c75ea73465e80818a3b526cc03d
Autor:
Rossella Farra, Francesco Musiani, Francesca Perrone, Maja Čemažar, Urška Kamenšek, Federica Tonon, Michela Abrami, Aleš Ručigaj, Mario Grassi, Gabriele Pozzato, Deborah Bonazza, Fabrizio Zanconati, Giancarlo Forte, Maguie El Boustani, Lucia Scarabel, Marica Garziera, Concetta Russo Spena, Lucia De Stefano, Barbara Salis, Giuseppe Toffoli, Flavio Rizzolio, Gabriele Grassi, Barbara Dapas
Publikováno v:
Molecules, Vol 23, Iss 4, p 777 (2018)
Despite the advances in anticancer therapies, their effectiveness for many human tumors is still far from being optimal. Significant improvements in treatment efficacy can come from the enhancement of drug specificity. This goal may be achieved by co
Externí odkaz:
https://doaj.org/article/28e4afc7e8c04115b85acbdf32a4e79a
Nanomechanical Characterization of Ovarian Cancer Cell Lines as a Marker of Response to 2c Treatment
Autor:
Domenico Tierno, Eros Azzalini, Rossella Farra, Sara Drioli, Fulvia Felluga, Marco Lazzarino, Gabriele Grassi, Barbara Dapas, Serena Bonin
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 8; Pages: 7230
Epithelial ovarian cancers (EOCs) are a heterogeneous group of tumors with different molecular and clinical features. In past decades, few improvements have been achieved in terms of EOC management and treatment efficacy, such that the 5-year surviva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93875df9c7086f965bb48833f958b546
https://doi.org/10.3390/ijms24087230
https://doi.org/10.3390/ijms24087230
Autor:
Gabriele Grassi, Barbara Dapas, Manuel Torralba, Marianna Maddaloni, Mario Grassi, Rossella Farra
Publikováno v:
Current Medicinal Chemistry. 27:7222-7233
Background: Ovary Carcinoma (OC) is the most lethal gynecological neoplasm due to the late diagnoses and to the common development of resistance to platinum-based chemotherapy. Thus, novel therapeutic approaches are urgently required. In this regard,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e6c74036a93c6b9be9e802b5ed859a
https://doi.org/10.2174/0929867327666200713190520
https://doi.org/10.2174/0929867327666200713190520